InnoCan Pharma Corporation
InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments: Online Sales and Other Operations. It engages in the research and development of CBD loaded exosomes, as well… Read more
Market Cap & Net Worth: InnoCan Pharma Corporation (INNPF)
InnoCan Pharma Corporation (OTCQB:INNPF) has a market capitalization of $629.83K ($629.83K) as of March 19, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #37504 globally and #12212 in its home market, demonstrating a 6.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying InnoCan Pharma Corporation's stock price $0.14 by its total outstanding shares 4498772 (4.50 Million).
InnoCan Pharma Corporation Market Cap History: 2019 to 2025
InnoCan Pharma Corporation's market capitalization history from 2019 to 2025. Data shows change from $994.23K to $629.83K (-20.07% CAGR).
InnoCan Pharma Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how InnoCan Pharma Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
InnoCan Pharma Corporation's market cap is 0.02 times its annual revenue
0.11x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.11 Million | $8.00K | -$9.95 Million | 138.79x | N/A |
| 2021 | $2.87 Million | $196.00K | -$10.05 Million | 14.66x | N/A |
| 2022 | $967.24K | $2.56 Million | -$3.76 Million | 0.38x | N/A |
| 2023 | $1.35 Million | $13.66 Million | -$4.70 Million | 0.10x | N/A |
| 2024 | $658.62K | $29.44 Million | -$1.83 Million | 0.02x | N/A |
Competitor Companies of INNPF by Market Capitalization
Companies near InnoCan Pharma Corporation in the global market cap rankings as of March 19, 2026.
Key companies related to InnoCan Pharma Corporation by market ranking:
- Procter & Gamble Company (NYSE:PG): Ranked #35 globally with a market cap of $351.41 Billion USD.
- Unilever PLC (PINK:UNLYF): Ranked #141 globally with a market cap of $131.81 Billion USD.
- UNILEVER PLC LS -,035 (XETRA:UNV0): Ranked #147 globally with a market cap of $126.11 Billion USD ( €122.86 Billion EUR).
- L'Oréal S.A (PINK:LRLCF): Ranked #215 globally with a market cap of $94.58 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #35 | Procter & Gamble Company | NYSE:PG | $351.41 Billion | $151.48 |
| #141 | Unilever PLC | PINK:UNLYF | $131.81 Billion | $60.96 |
| #147 | UNILEVER PLC LS -,035 | XETRA:UNV0 | $126.11 Billion | €56.81 |
| #215 | L'Oréal S.A | PINK:LRLCF | $94.58 Billion | $368.10 |
InnoCan Pharma Corporation Historical Marketcap From 2019 to 2025
Between 2019 and today, InnoCan Pharma Corporation's market cap moved from $994.23K to $ 629.83K, with a yearly change of -20.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $629.83K | -4.37% |
| 2024 | $658.62K | -51.20% |
| 2023 | $1.35 Million | +39.53% |
| 2022 | $967.24K | -66.34% |
| 2021 | $2.87 Million | +158.79% |
| 2020 | $1.11 Million | +11.67% |
| 2019 | $994.23K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of InnoCan Pharma Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $629.83K USD |
| MoneyControl | $629.83K USD |
| MarketWatch | $629.83K USD |
| marketcap.company | $629.83K USD |
| Reuters | $629.83K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.